PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Atopic dermatitis

Drugs in development · updated 30 October 2026

Atopic dermatitis: drugs in development

As of 30 October 2026 there are 111 active clinical trials (recruiting or ongoing, phases I–III) on 91 drugs for atopic dermatitis. 71 are experimental, that is not yet approved in the United States.

111Active trials
71Experimental drugs
15Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
AmlitelimabII–III4NCT05492578
StapokibartCM310, StapokibatrtIII3NCT06495229
TilrekimigPF-07275315III3NCT07783425
MG-K10III2NCT07540442
OPA-15406III2NCT07184645
VC005III2NCT07592585
GS101 injectionIII1NCT07386743
IBI3027III1NCT07754786
ICP-332III1NCT06775860
JaktinibIII1NCT05526222
PG-011GelIII1NCT06587685
QL2108III1NCT06884891
QY201III1NCT07180511
TLL-018II–III1NCT07784816
TQH2722III1NCT06552520
APG777II3NCT07003425
AfimkibartII2NCT07223697
CM512II2NCT07230483
ENV-294II2NCT07298395
IBI3002II2NCT07399067
IMG-007II2NCT07037901
LT-002-158I–II2NCT06931990
LutikizumabII2NCT06718101
AK120II1NCT06756126
ATI-045II1NCT07011706
BarzolvolimabII1NCT06727552
BempikibartADX-914II1NCT05509023
BFB759II1NCT07105488
CamoteskimabII1NCT07599813
EC-18II1NCT06487000
FB825II1NCT06397911
GalvokimigII1NCT07277660
GHZ339II1NCT06947993
GIA632II1NCT07220577
HL-300I–II1NCT07629778
HSK44459II1NCT06996912
HXN6005I–II1NCT07782476
JNJ-95597528II1NCT07230860
JYP0061II1NCT06158490
KT-621II1NCT07217015

Sorted by most advanced phase and number of active trials. Showing 40 of 71 drugs.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
DupilumabDUPIXENTIII9NCT07783425
UpadacitinibRinvoq Lq®, Rinvoq®III5NCT06461897
LebrikizumabEbglyss®III4NCT05735483
AbrocitinibCibinqo®III3NCT06807281
NemolizumabNemluvio®III1NCT07762833
PimecrolimusElidel®III1NCT06241118
RuxolitinibJakavi, Jakafi Xr®III1NCT06832618
TacrolimusEnvarsus XR, Prograf®III1NCT06241118
Tacrolimus ointment 0.1%III1NCT07162896
TralokinumabAdbry®, Adtralza®III1NCT06311682
TriamcinoloneII2NCT06994520
CephalexinKeftab®, Keflet®II1NCT01631617
DoxycyclineDoxycyclin, Lymepak®II1NCT01631617
RoflumilastZoryve®, Daliresp®II1NCT07297602
SulfamethoxazoleGantanol®, Gantanol-Ds®II1NCT01631617

Sorted by most advanced phase and number of active trials. Showing 15 of 20 drugs.

All 91 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D003876 “Dermatitis, Atopic”.

ItalianoFrançaisDeutsch